Whitehawk Therapeutics
WHWK
25 hedge funds and large institutions have $8.56M invested in Whitehawk Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 10 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
4% more funds holding
Funds holding: 24 → 25 (+1)
0.21% less ownership
Funds ownership: 1.77% → 1.56% (-0.21%)
53% less capital invested
Capital invested by funds: $18.3M → $8.56M (-$9.78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$387K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$330K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$271K |
| 5 |
BlackRock
New York
|
+$265K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.92M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$680K |
| 3 |
Citigroup
New York
|
-$411K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$282K |
| 5 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$246K |
WHWK Hedge Fund Activity: Q1 2019 in Review
25 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2019, worth a combined $8.56M — down 53% from $18.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new WHWK positions and 10 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.19M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.92M sold.
- 25 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2019, up from 24 in Q4 2018.
- Funds reported $8.56M of Whitehawk Therapeutics stock for Q1 2019, down 53% quarter-over-quarter.
- 11 funds opened new Whitehawk Therapeutics positions in Q1 2019 and 10 closed out, a net change of +1 holder.
- The largest Whitehawk Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $1.19M added.
- The largest Whitehawk Therapeutics seller in Q1 2019 was Sphera Funds Management, an estimated $1.92M sold.
Based on aggregated 13F filings for Q1 2019.